BioSyntech Inc.
TSX VENTURE : BSY

BioSyntech Inc.

October 11, 2006 09:30 ET

BioSyntech Receives Notice of Allowance from the US Patent and Trademark Office on Key BST-CarGel® Patent

LAVAL, CANADA--(CCNMatthews - Oct. 11, 2006) - BioSyntech, Inc. ("BioSyntech" or the "Company") (TSX VENTURE:BSY) announced today that on September 20, 2006, it received a Notice of Allowance from the US Patent and Trademark Office on their key BST-CarGel® patent entitled, "Composition and method for the repair and regeneration of cartilage and other tissues". BST-CarGel®, the Company's lead product, was designed to address the enormous clinical problem of cartilage damage and the inadequacies of current treatment options. The results of a major pre-clinical study, published in December 2005 in the prestigious Journal of Bone and Joint Surgery showed scientifically that BST-CarGel® regenerates more, higher quality cartilage than a common surgical procedure called microfracture.

"The acceptance of this patent is a major milestone for BioSyntech because it continues to solidify the intellectual property position of our technologies and products in the most important regions in the world, and protects our long-term viability," stated Claude LeDuc, President and CEO of BioSyntech. "The BST-CarGel® patent is now issued in 23 countries, including those in Europe."

The Company is currently enrolling patients in a Health Canada-approved pivotal trial for BST-CarGel®. This trial, which is studying the repair of cartilage damage in 80 subjects, will support BioSyntech's application for market approval in Canada and Europe. Data from the first 20 subjects will be submitted to the US FDA as pilot data in support of an Investigational Device Exemption application, leading to a pivotal trial in the US.

About the Intellectual Property of BioSyntech

BioSyntech recognizes the importance of intellectual property (IP), whether it be patents, trade-marks, or trade secrets, and is fully committed to maintaining a strong IP portfolio. In large part, BioSyntech's IP strength is derived from its platform technology, the BST-Gel®, along with further improvements and various uses thereof. Beginning with the original BST-Gel® patent, BioSyntech has continuously worked to more fully develop and understand the functionality of the gel and its variants leading to better protection of its ideas and to acquire market exclusivity. The portfolio currently comprises 70 patents and 40 pending patent applications in key countries. BioSyntech's portfolio also contains 30 registered trade-marks or trade-mark applications filed in key countries.

About BioSyntech

BioSyntech is a biotechnology company specializing in the discovery, development, and manufacturing of innovative, cost-effective, and physician-friendly therapeutic thermogels for regenerative medicine and therapeutic delivery. BioSyntech's quality management system is registered to ISO-9001; 2000 standard. For additional information, visit www.biosyntech.com.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information